Announcements Trials

Browse Landscape

Phase

Phase EARLY_PHASE1 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Neoplasms, Second Primary 1 Neoplasms 1

Interventions

pembrolizumab 44 Nivolumab 29 Gemcitabine 28 Paclitaxel 19 Cisplatin 18 Ipilimumab 15 Carboplatin 14 Cyclophosphamide 13 Capecitabine 12 Dexamethasone 10 Bevacizumab 10 cemiplimab 9 Irinotecan 9 Docetaxel 9 Albumin-Bound Paclitaxel 9 130-nm albumin-bound paclitaxel 9 spartalizumab 8 Pemetrexed 8 Sorafenib 7 Rituximab 7 Cetuximab 7 fludarabine 6 Temozolomide 6 Taxes 6 Radiotherapy 6 Leucovorin 6 Fluorouracil 6 Azacitidine 6 Ascorbic Acid 6 lenvatinib 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Neoplasms × Clonidine × Clear all

NCT00166686 2013-01-11

Clonidine for Neurocognitive Sequelae

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Phase 1/2 Withdrawn

Neoplasms, Neoplasms, Second Primary

Data powered by HemOnc (CC BY 4.0) Colophon ⚡